-+ 0.00%
-+ 0.00%
-+ 0.00%

IN8Bio Announced New Long-term Clinical Data From Its Fully Enrolled Phase 1 Trial Of INB-200 In Patients With Newly Diagnosed Glioblastoma Multiforme, Demonstrating Prolonged Progression-Free Survival

Benzinga·06/02/2025 11:32:27
Listen to the news
  • Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocol.
  • INB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observed.
  • Median PFS in patients receiving multiple doses of INB-200 exceeds the historical median overall survival (mOS) of 14.6 months with the SOC Stupp protocol; notably, four patients remain alive and progression free for a median of over two years